US2001036952A1PendingUtilityA1

Small molecule pipecolic acid derivative hair growth compositions and uses

Assignee: GUILFORD PHARM INCPriority: Jun 4, 1997Filed: Feb 16, 2001Published: Nov 1, 2001
Est. expiryJun 4, 2017(expired)· nominal 20-yr term from priority
A61P 17/14A61K 8/4913A61K 31/4439A61K 31/426A61K 2800/70A61K 31/4025A61K 31/4545A61K 31/401A61Q 7/00A61K 31/445A61K 31/40C07D 401/06C07D 417/12A61K 31/00C07D 401/12A61K 45/06
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using pipecolic acid derivatives.

Claims

exact text as granted — not AI-modified
We claim:  
     
         1 . A method for treating alopecia or promoting hair growth in an animal, which comprises administering to said animal an effective amount of a pipecolic acid derivative of formula I  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein: 
 A is CH 2 , O, NH, or N—(C 1 -C 4  alkyl);  
 B and D are independently Ar, C 5 -C 7  cycloalkyl substituted C 1 -C 6  straight or branched chain alkyl or C 2 -C 6  straight or branched chain alkenyl, C 5 -C 7  cycloalkenyl substituted C 1 -C 6  straight or branched chain alkyl or C 2 -C 6  straight or branched chain alkenyl, or Ar substituted C 1 -C 6  straight or branched chain alkyl or C 2 -C 6  straight or branched chain alkenyl, wherein in each case, one or two carbon atom(s) of said alkyl or alkenyl may be substituted with one or two heteroatom(s) independently selected from the group consisting of oxygen, sulfur, SO, and SO 2  in chemically reasonable substitution patterns, or  
                     wherein Q is hydrogen, C 1 -C 6  straight or branched chain alkyl or C 2 -C 6  straight or branched chain alkenyl; and    T is Ar or C 5 -C 7  cycloalkyl substituted at positions  3  and  4  with substituents independently selected from the group consisting of hydrogen, hydroxy, O—(C 1 -C 4  alkyl), O—(C 2 -C 4  alkenyl), and carbonyl;    
 Ar is selected from the group consisting of 1-napthyl, 2-napthyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl, monocyclic and bicyclic heterocyclic ring systems with individual ring sizes being 5 or 6 which contain in either or both rings a total of 1-4 heteroatoms independently selected from oxygen, nitrogen ard sulfur; wherein Ar contains 1-3 substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, hydroxymethyl, nitro, CF 3 , trifluoromethoxy, C 1 -C 6  straight or branched chain alkyl, C 2 -C 6  straight or branched chain alkenyl, O—(C 1 -C  4  straight or branched chain alkyl), O—(C 2 -C 4  straight or branched chain alkenyl), O-benzyl, O-phenyl, amino, 1,2-methylenedioxy, carbonyl, and phenyl;  
 L is either hydrogen or U; M is either oxygen or CH-U, provided that if L is hydrogen, then M is CH-U, or if M is oxygen then L is U;  
 U is hydrogen, O—(C 1 -C 4  straight or branched chain alkyl), O—(C 2 -C 4  straight or branched chain alkenyl), C 1 -C 6  straight or branched chain alkyl, C 2 -C 6  straight or branched chain alkenyl, C 5 -C 7  cycloalkyl, C 5 -C 7  cycloalkenyl substituted with C 1 -C 4  straight or branched chain alkyl or C 2 -C 4  straight or branched chain alkenyl, (C 1 -C 4  alkyl or C 2 -C 4  alkenyl) —Ar, or Ar;  
 J is hydrogen, C 1  or C 2  alkyl, or benzyl; K is C 1 -C 4  straight or branched chain alkyl, benzyl or cyclohexylmethyl; or J and K are taken together to form a 5-7 membered heterocyclic ring which is substituted with oxygen, sulfur, SO, or SO 2 ;  
 n is 0-3; and  
 said pipecolic acid derivative has an affinity for FKBP-type immunophilins.  
 
     
     
         2 . A method for treating alopecia or promoting hair growth in an animal, which comprises administering to said animal an effective amount of a pipecolic acid derivative of formula II  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein: 
 A is O, NH, or N-(C 1 -C 4  alkyl);  
 B is hydrogen, CHL-Ar, C 1 -C 6  straight or branched chain alkyl, C 2 -C 6  straight or branched chain alkenyl, C 5 -C 7  cycloalkyl, C 5 -C 7  cycloalkenyl, Ar substituted C 1 -C 6  alkyl or C 2 -C 6  alkenyl, or  
                     wherein L and Q are independently hydrogen, C 1 -C 6  straight or branched chain alkyl, or C 2 -C 6  straight or branched chain alkenyl; and    T is Ar or C 5 -C 7  cyclohexyl substituted at positions  3  and  4  with substituents independently selected from the group consisting of hydrogen, hydroxy, O—(C 1 -C 4  alkyl), O—(C 2 -C 4  alkenyl), and carbonyl;    
 Ar is selected from the group consisting of 1-napthyl, 2-napthyl, 2-furyl, 3-furyl, 2-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl having 1-3 substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, CF 3 , C 1 -C 6  straight or branched chain alkyl, C 2 -C 6  straight or branched chain alkenyl, O—(C 1 -C 4  straight or branched chain alkyl), O—(C 2 -C 4  straight or branched chain alkenyl), O-benzyl, O-phenyl, amino, and phenyl.  
 D is hydrogen or U; E is oxygen or CH-U, provided that if D is hydrogen, then E is CH-U, or if E is oxygen, then D is U;  
 U is hydrogen, O—(C 1 -C 4  straight or branched chain alkyl), O—(C 2 -C 4  straight or branched chain alkenyl), C 1 -C 6  straight or branched chain alkyl, C 2 -C 6  straight or branched chain alkenyl, C 5 -C 7 -cycloalkyl, C 5 -C 7  cycloalkenyl substituted with C 1 -C 4  straight or branched chain alkyl or C 2 -C 4  straight or branched chain alkenyl, 2-indolyl, 3-indolyl, (C 1 -C 4  alkyl or C 2 -C 4  alkenyl) —Ar, or Ar;  
 J is hydrogen, C 1  or C 2  alkyl, or benzyl; K is C 1 -C 4  straight or branched chain alkyl, benzyl or cyclohexylethyl; or J and K are taken together to form a 5-7 membered heterocyclic ring which is substituted with oxygen, sulfur, SO, or SO 2 .  
 
     
     
         3 . A method for treating alopecia or promoting hair growth in an animal, which comprises administering to said animal an effective amount of a pipecolic acid derivative of formula III  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein: 
 n is 2;  
 D is phenyl, methoxy, 2-furyl, or 3,4,5-trimethoxyphenyl; and  
 B is benzyl, 3-phenylpropyl, 4-(4-methoxyphenyl) butyl, 4-phenylbutyl, phenethyl, 3-cyclohexylpropyl, 4-cyclohexylbutyl, 3-cyclopentylpropyl, 4-cyclohexylbutyl, 3-phenoxybenzyl, 3-(3-indolyl)propyl, or 4- (4-methoxyphenyl)butyl;  
 provided that 
 when D is phenyl, then B is benzyl, 3-phenylpropyl, 4-(4-methoxyphenyl)butyl, 4-phenylbutyl, phenethyl, or 4-cyclohexylbutyl;  
 when D is methoxy, then B is benzyl, 4-cyclohexylbutyl, 3-cyclohexylpropyl, or 3-cyclopentylpropyl;  
 when D is 2-furyl, then B is benzyl; and  
 when D is 3,4,5-trimethoxyphenyl, then B is 4-cyclohexylbutyl, 3-phenoxybenzyl, 4-phenylbutyl, 3-(3-indolyl)propyl, or 4-(4-methoxyphenyl) butyl.  
 
 
     
     
         4 . A method for treating alopecia or promoting hair growth in an animal, which comprises administering to said animal an effective amount of a pipecolic acid derivative of formula IV  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein: 
 V is C, N, or S;  
 J and K, taken together with V and the carbon atom to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing, in addition to V, one or more heteroatom(s) selected from the group consisting of O, S, SO, SO 2 , N, NH, and NR;  
 R is either C 1 -C 9  straight or branched chain alkyl, C 2 -C 9  straight or branched chain alkenyl, C 3 -C 9  cycloakyl, C 5 -C 7  cycloalkenyl, or Ar 1 , wherein R is either unsubstituted of substituted with one or more substituent(s) independently selected from the group consisting of halo, haloalkyl, carbonyl, carboxy, hydroxy, nitro, trifluoromethyl, C 1 -C 6  straight or branched chain alkyl, C 2 -C 6  straight or branched chain alkenyl, C 1 -C 4  alkoxy, C 2 -C 4  alkenyloxy, phenoxy, benzyloxy, thioalkyl, alkylthio, sulfhydryl, amino, alkylamino, aminoalkyl, aminocarboxyl, and Ar 2 ;  
 Ar 1  and Ar 2  are independently an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring; wherein the individual ring size is 5-8 members; wherein said heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S;  
 A, B, D, L, M, and m are as defined in    claim 1    above; and  
 said pipecolic acid derivative has an affinity for FKBP-type immunophilins.  
 
     
     
         5 . A pharmaceutical composition which comprises: 
 (i) an effective amount of a pipecolic acid derivative for treating alopecia or promoting hair growth in an animal, wherein the pipecolic acid derivative is a compound of formula I                          or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:    A is CH 2 , O, NH, or N—(C 1 -C 4  alkyl);    B and D are independently Ar, C 5 -C 7  cycloalkyl substituted C 1 -C 6  straight or branched chain alkyl or C 2 -C 6  straight or branched chain alkenyl, C 5 -C 7  cycloalkenyl substituted C 1 -C 6  straight or branched chain alkyl or C 2 -C 6  straight or branched chain alkenyl, or Ar substituted C 1 -C 6  straight or branched chain alkyl or C 2 -C 6  straight or branched chain alkenyl, wherein in each case, one or two carbon atom(s) of said alkyl or alkenyl may be substituted with one or two heteroatom(s) independently selected from the group consisting of oxygen, sulfur, SO, and SO 2  in chemically reasonable substitution patterns, or                        wherein Q is hydrogen, C 1 -C 6  straight or branched chain alkyl or C 2 -C 6  straight or branched chain alkenyl; and    T is Ar or C 5 -C 7  cycloalkyl substituted at positions  3  and  4  with substituents independently selected from the group consisting of hydrogen, hydroxy, O—(C 1 -C 4  alkyl), O—(C 2 -C 4  alkenyl), and carbonyl;      Ar is selected from the group consisting of 1-napthyl, 2-napthyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl, monocyclic and bicyclic heterocyclic ring systems with individual ring sizes being 5 or 6 which contain in either or both rings a total of 1-4 heteroatoms is independently selected from oxygen, nitrogen and sulfur; wherein Ar contains 1-3 substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, hydroxymethyl, nitro, CF 3 , trifluoromethoxy, C 1 -C 6  straight or branched chain alkyl, C 2 -C 6  straight or branched chain alkenyl, O—(C 1 -C 4  straight or branched chain alkyl), O—(C 2 -C 4  straight or branched chain alkenyl) , O-benzyl, O-phenyl, amino, 1,2-methylenedioxy, carbonyl, and phenyl;    L is either hydrogen or U; M is either oxygen or CH-U, provided that if L is hydrogen, then M is CH-U, or if M is oxygen then L is U;    U is hydrogen, O—(C 1 -C 4  straight or branched chain alkyl), O—(C 2 -C 4  straight or branched chain alkenyl), C 1 -C 6  straight or branched chain alkyl, C 2 -C 6  straight or branched chain alkenyl, C 5 -C 7  cycloalkyl, C 5 -C 7  cycloalkenyl substituted with C 1 -C 4  straight or branched chain alkyl or C 2 -C 4  straight or branched chain alkenyl, (C 1 -C 4  alkyl or C 2 -C 4  alkenyl) —Ar, or Ar;    J is hydrogen, C 1  or C 2  alkyl, or benzyl; K is C 1 -C 4  straight or branched chain alkyl, benzyl or cyclohexylmethyl; or J and K are taken together to form a 5-7 membered heterocyclic ring which is substituted with oxygen, sulfur, SO, or SO 2 ;    n is 0-3; and    said pipecolic acid derivative has an affinity for FKBP-type immunophilins; and    (ii) a pharmaceutically acceptable carrier.    
     
     
         6 . A pharmaceutical composition which comprises: 
 (i) an effective amount of a pipecolic acid derivative for treating alopecia or promoting hair growth in an animal, wherein the pipecolic acid derivative is a compound of formula II                          or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:    A is O, NH, or N-(C 1 -C 4  alkyl);    B is hydrogen, CHL-Ar, C 1 -C 6  straight or branched chain alkyl, C 2 -C 6  straight or branched chain alkenyl, C 5 -C 7  cycloalkyl, C 5 -C 7  cycloalkenyl, Ar substituted C 1 -C 6  alkyl or C 2 -C 6  alkenyl, or                        wherein L and Q are independently hydrogen, C 1 -C 6  straight or branched chain alkyl, or C 2 -C 6  straight or branched chain alkenyl; and    T is Ar or C 5 -C 7  cyclohexyl substituted at positions  3  and  4  with substituents independently selected from the group consisting of hydrogen, hydroxy, O—(C 1 -C 4  alkyl), O—(C 2 -C 4  alkenyl), and carbonyl;      Ar is selected from the group consisting of 1-napthyl, 2-napthyl, 2-furyl, 3-furyl, 2-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl having 1-3 substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, CF 3 , C 1 -C 6  straight or branched chain alkyl, C 2 -C 6  straight or branched chain alkenyl, O—(C 1 -C 4  straight or branched chain alkyl), O—(C 2 -C 4  straight or branched chain alkenyl), O-benzyl, O-phenyl, amino, and phenyl.    D is hydrogen or U; E is oxygen or CH-U, provided that if D is hydrogen, then E is CH-U, or if E is oxygen, then D is U;    U is hydrogen, O—(C 1 -C 4  straight or branched chain alkyl), O—(C 2 -C 4  straight or branched chain alkenyl), C 1 -C 6  straight or branched chain alkyl, C 2 -C 6  straight or branched chain alkenyl, C 5 -C 7  cycloalkyl, C 5 -C 7  cycloalkenyl substituted with C 1 -C 4  straight or branched chain alkyl or C 2 -C 4  straight or branched chain alkenyl, 2-indolyl, 3-indolyl, (C 1 -C 4  alkyl or C 2 -C 4  alkenyl) —Ar, or Ar;    J is hydrogen, C 1  or C 2  alkyl, or benzyl; K is C 1 -C 4  straight or branched chain alkyl, benzyl or cyclohexylethyl; or J and K are taken together to form a 5-7 membered heterocyclic ring which is substituted with oxygen, sulfur, SO, or SO 2 ; and    (ii) a pharmaceutically acceptable carrier.    
     
     
         7 . A pharmaceutical composition which comprises: 
 (i) an effective amount of a pipecolic acid derivative for treating alopecia or promoting hair growth in an animal, wherein the pipecolic acid derivative is a compound of formula III                          or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:    n is 2;    D is phenyl, methoxy, 2-furyl, or 3,4,5-trimethoxyphenyl; and    B is benzyl, 3-phenylpropyl, 4-(4-methoxyphenyl) butyl, 4-phenylbutyl, phenethyl, 3-cyclohexylpropyl, 4-cyclohexylbutyl, 3-cyclopentylpropyl, 4-cyclohexylbutyl, 3-phenoxybenzyl, 3-(3-indolyl)propyl, or 4-(4-methoxyphenyl)butyl;    provided that 
 when D is phenyl, then B is benzyl, 3-phenylpropyl, 4-(4-methoxyphenyl)butyl, 4-phenylbutyl, phenethyl, or 4-cyclohexylbutyl;  
 when D is methoxy, then B is benzyl, 4-cyclohexylbutyl, 3-cyclohexylpropyl, or 3-cyclopentylpropyl;  
 when D is 2-furyl, then B is benzyl; and  
 when D is 3,4,5-trimethoxyphenyl, then B is 4-cyclohexylbutyl, 3-phenoxybenzyl, 4-phenylbutyl, 3-(3-indolyl)propyl, or 4-(4-methoxyphenyl) butyl; and  
   (ii) a pharmaceutically acceptable carrier.    
     
     
         8 . A pharmaceutical composition which comprises: 
 (i) an effective amount of a pipecolic acid derivative for treating alopecia or promoting hair growth in an animal, wherein the pipecolic acid derivative is a compound of formula formula IV                          or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:    V is C, N, or S;    J and K, taken together with V and the carbon atom to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing in addition to V, one or more heteroatom(s) selected from the group consisting of O, S, SO, SO 2 , N, NH, and NR;    R is either C 1 -C 9  straight or branched chain alkyl, C 2 -C 9  straight or branched chain alkenyl, C 3 -C 9  cycloakyl, C 5 -C 7  cycloalkenyl, or Ar 1 , wherein R is either unsubstituted of substituted with one or more substituent(s) independently selected from the group consisting of halo, haloalkyl, carbonyl, carboxy, hydroxy, nitro, trifluoromethyl, C 1 -C 6  straight or branched chain alkyl, C 2 -C 6  straight or branched chain alkenyl, C 1 -C 4  alkoxy, C 2 -C 4  alkenyloxy, phenoxy, benzyloxy, thioalkyl, alkylthio, sulfhydryl, amino, alkylamino, aminoalkyl, aminocarboxyl, and Ar 2 ;    Ar 1  and Ar 2  are independently an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring; wherein the individual ring size is 5-8 members; wherein said heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S;    A, B, D, L, M, and m are as defined in    claim 5    above; and    (ii) a pharmaceutically acceptable carrier.

Join the waitlist — get patent alerts

Track US2001036952A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.